Industry
Biotechnology
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Loading...
Open
11.82
Mkt cap
232M
Volume
2.1M
High
12.95
P/E Ratio
-2.14
52-wk high
21.66
Low
11.30
Div yield
N/A
52-wk low
6.50
Portfolio Pulse from Benzinga Newsdesk
August 24, 2023 | 5:57 am
Portfolio Pulse from richadhand@benzinga.com
August 22, 2023 | 1:41 pm
Portfolio Pulse from Happy Mohamed
August 17, 2023 | 12:04 pm
Portfolio Pulse from Benzinga Insights
August 15, 2023 | 9:00 pm
Portfolio Pulse from richadhand@benzinga.com
August 15, 2023 | 3:50 pm
Portfolio Pulse from Happy Mohamed
August 15, 2023 | 12:00 pm
Portfolio Pulse from Lara Goldstein
August 14, 2023 | 10:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.